^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Mesothelin-targeted CAR-T immunotherapy

    Related drugs:
    3ms
    Intraperitoneal CAR T-cell therapy for peritoneal carcinomatosis from gastroesophageal cancer: preclinical investigations to a phase I clinical trial (NCT06623396). (PubMed, J Immunother Cancer)
    Of note, intraperitoneal treatment also exhibits potency against distant disease sites. These findings provide a strong rationale for clinical translation; we are now conducting a clinical trial (NCT06623396) to evaluate intraperitoneal administration of M28z1XXPD1DNR CAR T cells in patients with gastroesophageal cancer peritoneal carcinomatosis.
    P1 data • Preclinical • Journal • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • MSLN (Mesothelin) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression
    |
    ATA2271
    4ms
    Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    MSLN (Mesothelin)
    |
    cyclophosphamide • ATA2271
    5ms
    A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, Outpace Bio, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    5ms
    A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Outpace Bio, Inc.
    New P1 trial
    6ms
    Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P=N/A, N=24, Recruiting, Zhejiang University
    New trial
    |
    cyclophosphamide • fludarabine IV • UCLM802
    6ms
    A Study of TAK-103 in Adult With Solid Tumors (clinicaltrials.gov)
    P1, N=2, Terminated, Takeda | Trial completion date: Oct 2027 --> Feb 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2027 --> Feb 2025; Business decision unrelated to patient safety
    Trial completion date • Trial termination • Trial primary completion date
    |
    MSLN (Mesothelin)
    |
    NIB103
    7ms
    Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov)
    P1/2, N=113, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    Keytruda (pembrolizumab) • cyclophosphamide • iCasp9M28z T cell infusion
    10ms
    A Long-Term Follow-Up Basket Study for Participants Treated with SynKIR Chimeric Antigen Receptor (CAR) T Cell Product (clinicaltrials.gov)
    P=N/A, N=60, Enrolling by invitation, Verismo Therapeutics | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    SynKIR-110
    11ms
    AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Arsenal Biosciences, Inc. | N=60 --> 19
    Enrollment change
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    cyclophosphamide • AB-1015
    1year
    A Long-Term Follow-Up Basket Study for Participants Treated with SynKIR Chimeric Antigen Receptor (CAR) T Cell Product (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, Verismo Therapeutics
    New trial • Pan tumor
    |
    SynKIR-110
    1year
    Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110 in Cancer Studies (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Verismo Therapeutics | N=100 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    SynKIR-110
    1year
    EVEREST-2: a seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity (SITC 2024)
    a May occur at any point in disease course. CRC, colorectal cancer; D, day; MESO, mesothelioma; NSCLC, non-small cell lung cancer; OVCA, ovarian cancer; PANC, pancreatic cancer; PCLD, preconditioning lymphodepletionDownload figure Open in new tab Download powerpoint Abstract 627 Figure 3 EVEREST-2 phase 1 dose escalation study design
    CAR T-Cell Therapy • P1/2 data • Clinical • IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin)
    |
    MSLN expression • HLA-A*02
    |
    Tempus HLA-LOH assay
    |
    liraltagene autoleucel (lira-cel)